J Paul Frindik
Overview
Explore the profile of J Paul Frindik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kemp S, Frindik J
Drug Des Devel Ther
. 2011 Oct;
5:411-9.
PMID: 21966214
Growth hormone (GH) was first used to treat a patient in 1958. For the next 25 years it was available only from cadaver sources, which was of concern because of...
2.
Thrailkill K, Moreau C, Swearingen C, Rettiganti M, Edwards K, Morales A, et al.
Diabetes Technol Ther
. 2011 Jul;
13(10):1023-30.
PMID: 21718094
Background: In the interest of preserving residual insulin secretory capacity present at the time of diagnosis with type 1 diabetes (T1D), we compared the efficacy of starting insulin pump therapy...
3.
Frindik J, Kemp S
Biologics
. 2010 Jul;
4:147-55.
PMID: 20631818
Idiopathic short stature (ISS) is a term that describes short stature in children who do not have growth hormone (GH) deficiency and in whom the etiology of the short stature...
4.
Frindik J, Morales A, Fowlkes J, Kemp S, Thrailkill K, Lippe B, et al.
Horm Res
. 2009 Sep;
72(3):160-6.
PMID: 19729947
Background/aims: Determine (1) frequency of attention-deficit hyperactivity disorder (ADHD) treatment and (2) growth responses in growth hormone (GH)-treated children who are receiving ADHD medication versus GH alone. Methods: Prepubertal children...
5.
Thrailkill K, Bunn R, Moreau C, Cockrell G, Simpson P, Coleman H, et al.
Diabetes Care
. 2007 Jun;
30(9):2321-6.
PMID: 17563344
Objective: Dysregulation of matrix metalloproteinase (MMP)-2 may contribute pathologically to the development of diabetes complications, including diabetic retinopathy and coronary and peripheral arterial disease. Our objective was to explore whether...
6.
Nimmo T, Morales A, Sayed K, Frindik J, Kemp S
Endocr Pract
. 2007 May;
13(2):198-201.
PMID: 17490937
No abstract available.
7.
Frindik J, Kemp S, Hunold J
J Pediatr Endocrinol Metab
. 2003 Jun;
16 Suppl 3:607-12.
PMID: 12795361
Objective: Determination of near adult height (NAH) after recombinant human growth hormone (rhGH) therapy in patients with idiopathic short stature (ISS, maximum stimulated growth hormone [MSGH] > 10 ng/ml) or...
8.
Frindik J, Williams J, Johnson R, Dykman R
Endocr Pract
. 2002 Apr;
8(2):105-8.
PMID: 11942774
Objective: To compare subjective parental perceptions of short-term diabetes control with objective glycated hemoglobin (HbA1c) measurements in a pediatric population. Methods: Parents of 159 children and adolescents with type 1...